GlassScriptPhysician profile
Tony Lee
NPI 1316536410
$3,839.41
in general payments reported to CMS, 2019-2025
23 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $1,836 · 2023: $659 · 2024: $778 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,570.88 | 2022-2025 | Corevalve Evolut R, Venaseal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $560.38 | 2021-2025 | Lifevest |
| Lantheus Medical Imaging, INC. | $229.84 | 2022-2023 | Definity |
| Novartis Pharmaceuticals Corporation | $199.69 | 2022-2025 | |
| Amgen INC. | $170.34 | 2024-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $158.87 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kiniksa Pharmaceuticals International, Plc | $149.59 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $141.17 | 2021-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $121.24 | 2024 | |
| Abiomed | $96.58 | 2023 | Impella |
| Glaxosmithkline, LLC. | $80.66 | 2021-2025 | Shingrix |
| Boston Scientific Corporation | $63.43 | 2022-2023 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $52.70 | 2024 | |
| Veryan Medical Incorporated | $40.51 | 2023 | Biomimics 3d Vascular Stent System |
| Chiesi USA, INC. | $32.08 | 2022-2025 | Kengreal |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.82 | 2024 | Evkeeza |
| Axsome Therapeutics, INC. | $24.41 | 2025 | Symbravo |
| Pfizer INC. | $21.92 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.94 | 2025 | Wainua |
| Siemens Medical Solutions USA, INC. | $20.63 | 2022 | |
| Lilly USA, LLC | $20.11 | 2024 | Zepbound, Mounjaro |
| Teleflex LLC | $17.51 | 2022 | |
| Organon LLC | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.